Atara Biotherapeutics Inc (ATRA): Next-Year EPS Estimate 169.11%
As of 2026-06-04, Atara Biotherapeutics Inc (ATRA) has a next-year EPS growth estimate of 169.11%.
On 2026-05-31, analyst consensus for ATRA's next-year EPS growth shifted from 183.57% to 169.11% — a negative change of 14.46 percentage points. The revised estimate has been sustained across 5 subsequent trading sessions. Current-year growth is projected at -150.39%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 169.11%
- EPS growth this year
- -150.39%
- EPS next quarter (est)
- -$0.32
- Last price
- $10.27
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 169.11% | -150.39% | -$0.32 | $10.27 |
| 2026-06-03 | 169.11% | -150.39% | -$0.32 | $9.63 |
| 2026-06-02 | 169.11% | -150.39% | -$0.32 | $9.90 |
| 2026-06-01 | 169.11% | -150.39% | -$0.32 | $10.28 |
| 2026-05-31 | 169.11% | -150.39% | -$0.32 | $10.51 |
| 2026-05-28 | 183.57% | -130.96% | -$0.22 | $11.26 |
| 2026-05-27 | 183.57% | -130.96% | -$0.22 | $10.54 |
| 2026-05-26 | 183.57% | -130.96% | -$0.22 | $9.61 |
| 2026-05-25 | 183.57% | -130.96% | -$0.22 | $9.80 |
| 2026-05-24 | 183.57% | -130.96% | -$0.22 | $9.80 |
| 2026-05-21 | 183.57% | -130.96% | -$0.22 | $9.34 |
| 2026-05-20 | 183.57% | -130.96% | -$0.22 | $9.45 |
| 2026-05-19 | 183.57% | -130.96% | -$0.22 | $9.41 |
| 2026-05-18 | 183.57% | -130.96% | -$0.22 | $9.15 |
| 2026-05-17 | 107.53% | -126.68% | -$0.24 | $9.58 |
| 2026-05-14 | 107.53% | -126.68% | -$0.24 | $9.59 |
| 2026-05-13 | 107.53% | -126.68% | -$0.24 | $10.24 |
| 2026-05-12 | 105.59% | -126.68% | -$0.33 | $9.81 |
| 2026-05-11 | 105.59% | -126.68% | -$0.33 | $8.78 |
| 2026-05-07 | 182.21% | -116.21% | -$0.25 | $9.87 |
Recent News
- Atara Biotherapeutics: Q1 Earnings SnapshotAssociated Press
- Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational ProgressBusiness Wire
- FDA Resubmission Path for Tab-cel Keeps Ataras (ATRA) Regulatory Timeline AliveInvestorsHub
- FDA Resubmission Path for Tab-cel Keeps Ataras (ATRA) Regulatory Timeline AliveInvestorsHub
- BC-Most Active StocksAssociated Press
- Atara Biotherapeutics Provides Regulatory Update on TabelecleucelBusiness Wire
- Atara Biotherapeutics Provides Regulatory Update on TabelecleucelBusiness Wire
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Atara Biotherapeutics Inc's next-year EPS growth estimate?▾
As of 2026-06-04, Atara Biotherapeutics Inc (ATRA) has a next-year EPS growth estimate of 169.11%, based on analyst consensus.
When was the latest EPS estimate revision for ATRA?▾
The most recent revision occurred on 2026-05-31, when analysts adjusted the next-year EPS growth estimate from 183.57% to 169.11%.
What sector and industry does Atara Biotherapeutics Inc belong to?▾
Atara Biotherapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. ATRA appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Atara Biotherapeutics Inc (ATRA) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports